间充质干细胞移植治疗心肌梗死的研究现状及优化策略

The Research Status and Optimizing Strategy of Mesenchymal Stem Cells Therapy for Myocardial Infarction

心肌梗死(myocardial infarction,MI)仍然是世界范围内致死致残的主要原因之一,尽管药物和介入治疗能够及时恢复心脏血供,但心肌细胞极低的自我再生能力仍无法挽救急性受损的心肌组织,MI严重时可导致心脏衰竭乃至死亡的发生。目前,基础与临床研究均显示间充质干细胞(mesenchymal stem cells,MSCs)能够通过旁分泌等效应显著改善MI后的心功能修复且经特定条件优化改进的MSCs已经在MI等疾病的治疗中显得愈发重要。因此,该文将从MSCs移植治疗MI的研究现状、修复机制、移植途径以及优化策略几方面分别进行综述。

Heart failure after MI(myocardial infarction)remains one of the leading causes of death and disability worldwide.Although drugs and interventional therapy can restore blood supply to the heart timely,the regenerative capacity of myocardial cells is too low to improve damaged heart function,which can seriously lead to heart failure and even death.At present,both basic and clinical studies have shown that MSCs(mesenchymal stem cells)can effectively improve the repair of cardiac function after MI,and optimized and improved MSCs have become increasingly important in the treatment of MI and other diseases.Therefore,this article will respectively review the progress of the primary mechanism of MSCs,the recent status of MSCs and transplantation pathway and the optimizing strategy in the treatment of myocardial infarction.